Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MMP2 | P08253 | 1/20 | 0.52 |
| ▸ | CES1 | P23141 | 4/20 | 0.46 |
| ▸ | FAAH | O00519 | 4/20 | 0.46 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.45 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
| ▸ | RNASEH1 | O60930 | 1/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | MGLL | Q99685 | 1/20 | 0.41 |
| ▸ | KDM5B | Q9UGL1 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11317135 | 0.87 | PTGIR (0.48) | CES1FAAHGSK3BRNASEH1CYP1A2 | |
| SCHEMBL7429208 | 0.81 | L3MBTL1 (0.52) | GSK3BSMN1; SMN2LMNA | |
| Bromide SCHEMBL7432518 | 0.78 | NPSR1 (0.37) | MMP2CES1FAAHGSK3BCYP1A2 | |
| SCHEMBL7006107 | 0.78 | NPSR1 (0.37) | MMP2CES1FAAHGSK3BKDM4E | |
| SCHEMBL11001539 | 0.78 | FBP1 (0.39) | FAAHSMN1; SMN2LMNAMEN1KMT2A | |
| SCHEMBL12203721 | 0.77 | L3MBTL1 (0.49) | KDM4ELMNAKMT2A | |
| SCHEMBL11829444 | 0.76 | CES1 (0.45) | MMP2CES1FAAHDAGLARNASEH1 | |
| SCHEMBL6656900 | 0.75 | SMN1; SMN2 (0.43) | MMP2CES1FAAHDAGLAGSK3B | |
| SCHEMBL21776794 | 0.75 | KDM4E (0.50) | MMP2CES1FAAHKDM4EMEN1 | |
| SCHEMBL12138862 | 0.73 | SMN1; SMN2 (0.45) | SMN1; SMN2KDM4ELMNAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1317459-B1 | BICYCLIC PYRROLYL AMIDES AS GLUCOGEN PHOSPHORYLASE INHIBITORS | ASTRAZENECA AB (SE) | 2004-04-07 | — | — | EP | disclosed |
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | ASTRAZENECA AB (SE) | 2003-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030232875-A1 | Bicyclic pyrrolyl amides as glucogen phosphorylase inhibitors | GYS1, GYS2, PYGL | MMP2 468/4885CES1 359/4885FAAH 4733/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.